Organization
Astellas Pharma Inc.
14 abstracts
Abstract
Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.Org: Dana-Farber Cancer Institute, University of Wisconsin, University of California Irvine, University of Colorado Denver Department of Radiation Oncology, Perlmutter Cancer Center, NYU Langone Health,
Abstract
Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC).Org: Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, Université Paris-Sud, Université Paris-Saclay, Netherlands Cancer Institute,
Abstract
EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL).Org: IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy, Department of Urology and Research Program in Systems Oncology, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland, Instituto Valenciano de Oncologia, Valencia, Spain, Astellas Pharma Inc., Northbrook, IL, Pfizer Inc., New York, NY,
Abstract
Real-world first-line treatment patterns and outcomes in patients with locally advanced or metastatic urothelial carcinoma in the United States.Org: University of Kansas Medical Center, Department of Biostatistics & Data Science, Astellas Pharma Inc., Astellas Pharma, Inc., Analysis Group, Inc., Pfizer Inc.,
Abstract
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL).Org: Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Memorial Sloan Kettering Cancer Center, Vancouver Prostate Centre, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori,
Abstract
Enfortumab vedotin in the previously treated advanced head and neck cancer (HNC) cohort of EV-202.Org: University of Michigan Medical School, Cleveland Clinic Taussig Cancer Instititute, University of Chicago, National Cancer Center East Hospital, University of Wisconsin, Madison,
Abstract
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.Org: Astellas Pharma Inc., Seagen, Inc.,
Abstract
Longitudinal transcriptome profiling of localized hormone-sensitive tumors in treatment-naïve ENACT patients with prostate cancer with and without enzalutamide (ENZA).Org: Northwestern University Feinberg School of Medicine, Carolina Urologic Research Center, Veracyte, Inc., Astellas Pharma Inc., Pfizer Inc., London, United Kingdom,
Abstract
A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, UT Southwestern Medical Center, Hôpital Pitié-Salpêtrière, NYU Department of Urology, Perlmutter Cancer Center, New York University Langone Health,
Abstract
Enfortumab vedotin (EV) with or without pembrolizumab (P) in patients (pts) who are cisplatin-ineligible with previously untreated locally advanced or metastatic urothelial cancer (la/mUC): Additional 3-month follow-up on cohort K data.Org: University of California, San Francisco Medical Center, University of North Carolina, Lineberger Comprehensive Cancer Center, University of Chicago, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Duke Cancer Institute,
Abstract
Real-world use, dose intensity, and adherence to enfortumab vedotin (EV) in locally advanced or metastatic urothelial cancer (la/mUC).Org: Astellas Pharma Inc., Astellas Pharma, Abramson Cancer Center,
Abstract
Real-world baseline characteristics and first-line (1L) treatment (Tx) in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC) by disease volume.Org: Center for Integrated Research in Cancer and Lifestyle, Cedars-Sinai Medical Center, Formerly of Astellas Pharma Inc., Current affiliation, Pfizer Inc., Astellas Pharma Inc.,
Abstract
Outcomes of patients (pts) with de novo metastatic hormone-sensitive prostate cancer (mHSPC) who progressed to metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TRUMPET registry.Org: Northshore University Health System, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Levine Cancer Institute, Atrium Health Carolinas Medical Center, Carolina Urologic Research Center,
Abstract
EV-203: Phase 2 trial of enfortumab vedotin in patients with previously treated advanced urothelial carcinoma in China.Org: Astellas (China) Investment Co., Ltd, Seagen, Bothell, WA, Astellas Pharma, Inc., Astellas Pharma Inc.,